Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium
Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium
Sponsor: AbbVie
Listed as NCT02581163, this observational or N/A phase trial focuses on Chronic Hepatitis C, Genotype 1 or 4 and remains completed. Sponsored by AbbVie, it has been updated 11 times since 2015, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2019 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Jun 2019 [monthly]
Completed
▶ Show 6 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Aug 2017 — Mar 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jun 2017 — Aug 2017 [monthly]
Recruiting NA
-
Feb 2017 — Jun 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
- IST GmbH, Germany
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.